Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Nimodipine
Generic Name
Nimodipine
Active Ingredient
NimodipineCategory
Dihydropyridine Calcium Channel Blocker [EPC]
Variants
3
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Nimodipine, you must consult a qualified healthcare professional.
Detailed information about Nimodipine
Nimodipine is a dihydropyridine calcium channel blocker specifically indicated for the improvement of neurological outcomes following subarachnoid hemorrhage by reducing the incidence and severity of ischemic deficits.
The standard adult dosage for nimodipine in the treatment of subarachnoid hemorrhage (SAH) is highly standardized to ensure constant therapeutic levels. The typical regimen is 60 mg (two 30 mg capsules or 20 mL of oral solution) administered every 4 hours. This dosing schedule must be maintained consistently for 21 consecutive days. Therapy should ideally begin within 96 hours of the onset of the hemorrhage. If the patient's blood pressure drops significantly, the healthcare provider may adjust the dose or the frequency, but the 60 mg q4h (every 4 hours) remains the clinical benchmark for efficacy.
Nimodipine is not currently FDA-approved for use in pediatric patients. The safety and effectiveness of this medication in children under the age of 18 have not been established. In rare, life-threatening circumstances, pediatric neurosurgeons may use nimodipine off-label, but there is no standardized weight-based dosing guide available for the general public. Any use in children must be strictly managed by a specialist.
Specific dosage adjustments for patients with renal (kidney) impairment are generally not required, as nimodipine is primarily metabolized by the liver. However, because the metabolites are excreted via the kidneys, patients with severe renal failure should be monitored closely for any unexpected side effects.
Patients with hepatic (liver) impairment, such as cirrhosis, require significant dosage adjustments. Because the liver is responsible for breaking down nimodipine, impaired function can lead to dangerously high levels of the drug in the blood. In patients with severe hepatic dysfunction, the dose is typically reduced to 30 mg every 4 hours, and blood pressure must be monitored with extreme vigilance.
Geriatric patients may be more sensitive to the hypotensive (blood pressure lowering) effects of nimodipine. While the starting dose is often the same as in younger adults, healthcare providers may monitor elderly patients more frequently for signs of lightheadedness, fainting, or kidney strain due to low blood pressure.
Nimodipine must be taken exactly as prescribed, typically around the clock (e.g., 12 AM, 4 AM, 8 AM, 12 PM, 4 PM, 8 PM).
If a dose of nimodipine is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose (within 1-2 hours), the missed dose should be skipped. Patients should never 'double up' on doses to make up for a missed one. Maintaining a consistent 4-hour interval is vital for preventing the cerebral vasospasm that the drug is intended to treat.
An overdose of nimodipine is a medical emergency. Symptoms of overdose are primarily related to excessive vasodilation and may include:
In the event of a suspected overdose, contact emergency services (911 in the U.S.) or a poison control center immediately. Treatment typically involves supportive care, intravenous fluids to raise blood pressure, and potentially the use of vasopressors (medications that constrict blood vessels).
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. The timing of nimodipine is critical to its success in preventing brain injury.
The most frequently reported side effect of nimodipine is hypotension (low blood pressure). Because nimodipine is a vasodilator, it relaxes blood vessels throughout the body, not just in the brain.
Nimodipine is a high-alert medication that must be managed by healthcare professionals in a hospital setting. The most important safety consideration is the prevention of administration errors. Patients and caregivers must be aware that this medication is never to be given by any route other than the mouth or a feeding tube. Furthermore, because nimodipine affects the cardiovascular system, it must be used with caution in patients with unstable heart conditions or those taking other medications that lower blood pressure.
Deaths and serious, life-threatening adverse events, including cardiac arrest, severe hypotension, and cardiovascular collapse, have occurred when the contents of nimodipine capsules have been injected intravenously. If nimodipine is extracted from a capsule for administration via a feeding tube, it must be administered using a syringe specifically labeled 'Not for IV Use.' The use of the oral solution formulation is preferred to minimize the risk of administration errors.
Nimodipine is primarily metabolized by the CYP3A4 enzyme. Therefore, the use of strong CYP3A4 inducers is strictly contraindicated, as they can reduce nimodipine levels in the blood to the point where the drug becomes completely ineffective. Examples include:
Using these together can lead to a failure of therapy, increasing the risk of permanent brain damage from vasospasm.
Nimodipine must NEVER be used in the following circumstances:
In some cases, the benefits of nimodipine may outweigh the risks, but extreme caution is required:
Nimodipine is classified as Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus (such as skeletal abnormalities and stunted growth), but there are no adequate and well-controlled studies in humans. Nimodipine should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. In the case of a life-threatening subarachnoid hemorrhage, the mother's survival and neurological health are prioritized, but the medical team must be aware of the potential teratogenic risks.
Studies have shown that nimodipine and its metabolites are excreted in rat milk. While there is limited data on human breast milk, it is generally assumed that nimodipine will pass into the milk. Because of the potential for serious adverse reactions in nursing infants (such as low blood pressure), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Most experts recommend against breastfeeding while taking nimodipine.
The safety and effectiveness of nimodipine in pediatric patients have not been established. There is no FDA-approved dosing for children. While some pediatric neurosurgeons may use it in rare cases of childhood stroke or hemorrhage, this is done with extreme caution and without the support of large-scale clinical trials.
Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts by binding to L-type (long-lasting) voltage-gated calcium channels in the membranes of vascular smooth muscle and neurons. By inhibiting the transmembrane influx of calcium ions, nimodipine prevents the calcium-dependent contraction of arterial smooth muscle. Its specific efficacy in subarachnoid hemorrhage is attributed to its high lipophilicity, which allows it to cross the blood-brain barrier and target cerebral arteries more effectively than other drugs in its class. It prevents the delayed cerebral ischemia (DCI) that typically occurs 4 to 14 days after a brain bleed.
The primary pharmacodynamic effect of nimodipine is vasodilation, particularly in the cerebral vasculature. In humans, nimodipine increases cerebral blood flow and reduces the resistance of brain vessels. It has a minimal effect on the heart's conduction system (unlike verapamil or diltiazem) but can cause a decrease in systemic vascular resistance, leading to a drop in blood pressure. The onset of action is rapid (within 1 hour), and the duration of effect is relatively short, which is why it requires dosing every 4 hours.
Common questions about Nimodipine
Nimodipine is primarily used to improve neurological outcomes in patients who have suffered a subarachnoid hemorrhage, which is a type of bleeding in the brain caused by a ruptured aneurysm. It works by preventing 'delayed ischemic neurological deficits,' a complication where the brain's blood vessels narrow and restrict blood flow in the days following the initial bleed. By blocking calcium channels in the cerebral arteries, nimodipine helps maintain blood flow to the brain and protects nerve cells from damage. It is typically given for a 21-day course starting shortly after the hemorrhage occurs. While it is a calcium channel blocker, it is not used for the routine treatment of high blood pressure.
The most common side effect of nimodipine is low blood pressure, also known as hypotension, which occurs because the medication relaxes blood vessels throughout the body. Patients may experience lightheadedness, dizziness, or a feeling of warmth and flushing. Other frequent side effects include headaches, nausea, and changes in heart rate, such as a faster or slower pulse. In a hospital setting, medical staff will monitor your blood pressure and heart rate very closely to manage these effects. Most of these side effects are manageable and resolve once the 21-day treatment course is completed.
No, you should not drink alcohol while taking nimodipine. Both alcohol and nimodipine cause your blood vessels to dilate (widen), and combining them can lead to a dangerous and sudden drop in blood pressure. This can result in severe dizziness, fainting, and an increased risk of injury. Since nimodipine is used to treat a serious brain condition, it is vital to avoid any substances that could interfere with your blood pressure or neurological stability. Always consult your healthcare provider before consuming any alcohol if you have recently finished a course of this medication.
Nimodipine is classified as a Pregnancy Category C medication, meaning that animal studies have shown potential harm to the fetus, but there is not enough data from human studies to confirm its safety. It should only be used during pregnancy if the potential benefit to the mother—such as surviving a life-threatening brain bleed—outweighs the potential risks to the unborn baby. If you are pregnant or planning to become pregnant, your medical team will carefully weigh these risks in an emergency situation. Breastfeeding is generally not recommended while taking nimodipine as the drug may pass into breast milk and affect the infant.
Nimodipine begins to work relatively quickly after it is taken, with peak levels in the bloodstream usually reached within one hour. However, its 'work' in the context of subarachnoid hemorrhage is preventative rather than immediate symptom relief. It is started within 96 hours of the brain bleed to prevent the blood vessels from spasming, which typically happens between day 4 and day 14 after the event. You may not 'feel' the drug working, but it is actively protecting your brain tissue from secondary damage during the critical recovery window. It must be taken consistently every 4 hours to maintain this protection.
You should never stop taking nimodipine suddenly or finish the course early unless specifically instructed by your doctor. The standard treatment course is 21 days because the risk of cerebral vasospasm (dangerous narrowing of the brain's blood vessels) remains high for several weeks after a subarachnoid hemorrhage. Stopping the medication early could leave your brain vulnerable to a secondary stroke or permanent neurological damage. Once the 21-day course is finished, the medication can usually be stopped without any need for tapering. Always follow the full schedule prescribed by your neurosurgical team.
If you miss a dose of nimodipine, you should take it as soon as you remember. However, if it is almost time for your next scheduled dose, you should skip the missed dose and return to your regular 4-hour schedule. Do not take two doses at the same time to make up for a missed one, as this could cause your blood pressure to drop to a dangerous level. Because the timing of this medication is so important for preventing brain injury, many patients or their caregivers use alarms to stay on track. If you are in the hospital, the nursing staff will manage the timing for you.
Weight gain is not a common or expected side effect of nimodipine. While some other types of calcium channel blockers can cause fluid retention and swelling (edema) in the ankles and feet, which might lead to a slight increase in scale weight, this is rarely a significant issue with the short 21-day course of nimodipine. If you notice rapid weight gain or sudden swelling while taking this medication, you should inform your healthcare provider immediately. This could be a sign of fluid overload or a rare effect on your heart function rather than typical 'fat' weight gain.
Nimodipine has many significant drug interactions, particularly with medications that affect liver enzymes (CYP3A4). It should not be taken with certain seizure medications (like phenytoin), certain antibiotics (like rifampin), or herbal supplements like St. John's Wort, as these can make nimodipine ineffective. Conversely, other drugs like antifungal medications or certain heart medicines can make nimodipine levels too high, increasing the risk of side effects. It is also important to avoid grapefruit juice. Always provide your doctor with a complete list of all medications, vitamins, and supplements you are taking to ensure your safety.
Yes, nimodipine is available as a generic medication in the form of 30 mg liquid-filled capsules. The availability of generic versions has made the treatment more accessible and cost-effective for hospitals and patients. There is also a branded oral solution called Nymalize, which is often used in hospital settings to ensure accurate dosing and to prevent the dangerous error of accidental intravenous injection. Whether you receive the generic capsules or the branded solution, the active ingredient and the required 21-day dosing schedule remain the same.
Other drugs with the same active ingredient (Nimodipine)
> Warning: Stop taking Nimodipine and call your doctor immediately if you experience any of these.
Nimodipine is intended for short-term use (21 days). Consequently, there is limited data on the long-term side effects of this specific drug. However, chronic use of other drugs in this class can lead to gingival hyperplasia (overgrowth of the gums) and persistent peripheral edema. Because nimodipine is used in a critical care context, the focus is on acute management rather than long-term maintenance.
Nimodipine has a critical FDA Black Box Warning regarding its administration. There have been numerous reports of death and life-threatening cardiovascular events when the liquid contents of nimodipine capsules were accidentally injected intravenously (into a vein).
Report any unusual symptoms to your healthcare provider. Monitoring in an Intensive Care Unit (ICU) is standard for patients receiving this medication.
Patients taking nimodipine require frequent and intensive monitoring:
Nimodipine can cause dizziness, lightheadedness, and low blood pressure. Patients receiving nimodipine for subarachnoid hemorrhage are typically hospitalized and not in a condition to drive. However, if used in an outpatient setting for off-label purposes, patients should not drive or operate heavy machinery until they know how the medication affects them.
Alcohol should be strictly avoided while taking nimodipine. Alcohol acts as a vasodilator and can significantly enhance the blood pressure-lowering effects of nimodipine, leading to a high risk of fainting, severe hypotension, and injury.
Nimodipine is typically taken for exactly 21 days. There is no evidence of a 'withdrawal syndrome' or a need for tapering when stopping the drug after the 21-day course. However, the medication should never be stopped early unless directed by a physician, as the risk of cerebral vasospasm remains high for several weeks following a subarachnoid hemorrhage.
> Important: Discuss all your medical conditions, especially liver disease or heart problems, with your healthcare provider before starting Nimodipine.
Conversely, strong CYP3A4 inhibitors can cause nimodipine levels to skyrocket, leading to dangerous hypotension. If these must be used, the nimodipine dose may need to be reduced, and blood pressure must be monitored constantly. Examples include:
Nimodipine is not known to significantly interfere with most common laboratory tests (such as basic metabolic panels or complete blood counts). However, it may occasionally cause a false elevation in liver function tests due to its metabolic pathway. Always inform the laboratory and your physicians of all medications you are taking.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete list is essential to prevent dangerous interactions during your recovery.
Patients who have had a severe adverse reaction to other dihydropyridine calcium channel blockers (such as nifedipine, felodipine, or nicardipine) may be at an increased risk of a similar reaction to nimodipine. While they are chemically distinct, their shared structure means that a patient who experienced angioedema (severe swelling) with one may experience it with the other.
> Important: Your healthcare provider will evaluate your complete medical history, including liver function and current medications, before prescribing Nimodipine. This assessment is vital for your safety.
Clinical studies of nimodipine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, in general, elderly patients are more likely to have decreased hepatic or renal function and may be taking multiple other medications (polypharmacy). This increases the risk of drug interactions and severe hypotension. In older adults, blood pressure and kidney function should be monitored more frequently, and the risk of falls due to dizziness must be managed.
While the kidneys are not the primary route of nimodipine metabolism, they are responsible for excreting the inactive metabolites. In patients with significant renal impairment (GFR < 30 mL/min), there is a theoretical risk of metabolite accumulation. However, no specific dose adjustment is currently recommended by the FDA for renal failure. Monitoring of fluid balance and blood pressure is sufficient.
This is the most critical special population for nimodipine. Hepatic impairment (liver disease) significantly increases the 'area under the curve' (AUC) and peak plasma concentration (Cmax) of nimodipine.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have a history of liver disease.
|---|---|
| Bioavailability | ~13% (Extensive first-pass metabolism) |
| Protein Binding | >95% (Primarily to albumin) |
| Half-life | 8-9 hours (Terminal); 1-2 hours (Initial) |
| Tmax | 1 hour |
| Metabolism | Hepatic (CYP3A4) |
| Excretion | Renal (50% as metabolites), Fecal (32%) |
Nimodipine is classified as a Dihydropyridine Calcium Channel Blocker [EPC]. Other medications in this class include nifedipine, amlodipine, and nicardipine. However, nimodipine is the only member of this class specifically indicated for the management of subarachnoid hemorrhage due to its unique ability to penetrate the central nervous system.